Lead agent William Blair sells stock at $18.50 per share through deal
By Devika Patel
Knoxville, Tenn., May 27 – Aclaris Therapeutics, Inc. said it will raise $20 million in a private placement of stock. William Blair was the lead agent and Guggenheim Securities was the co-placement agent.
The company will sell 1,081,082 common shares at $18.50 apiece. The purchase price is a 6.09% discount to the May 26 closing share price of $19.70.
Aisling Capital is the lead investor.
Settlement is expected June 2.
Proceeds will be used for search and development, including new JAK inhibitor programs for androgenetic alopecia and vitiligo, as well as business development.
The pharmaceutical company is based in Malvern, Pa.
| Issuer: | Aclaris Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $20 million
|
| Shares: | 1,081,082
|
| Price: | $18.50
|
| Warrants: | No
|
| Agents: | William Blair (lead), Guggenheim Securities (co-placement agent)
|
| Investor: | Aisling Capital (lead)
|
| Pricing date: | May 27
|
| Settlement date: | June 2
|
| Stock symbol: | Nasdaq: ACRS
|
| Stock price: | $19.70 at close May 26
|
| Market capitalization: | $402.88 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
